216 related articles for article (PubMed ID: 22054231)
21. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
Usman M; Frey OR; Hempel G
Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
[TBL] [Abstract][Full Text] [Related]
22. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.
VanScoy BD; Trang M; McCauley J; Conde H; Bhavnani SM; Friedrich LV; Alexander DC; Ambrose PG
Antimicrob Agents Chemother; 2016 Jul; 60(7):3891-6. PubMed ID: 27001820
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
25. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
Corcione S; D'Avolio A; Loia RC; Pensa A; Segala FV; De Nicolò A; Fatiguso G; Romeo M; Di Perri G; Stella M; De Rosa FG
J Glob Antimicrob Resist; 2020 Mar; 20():22-27. PubMed ID: 31207380
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.
Cojutti P; Maximova N; Pea F
Antimicrob Agents Chemother; 2015 Sep; 59(9):5535-41. PubMed ID: 26124157
[TBL] [Abstract][Full Text] [Related]
29. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
[TBL] [Abstract][Full Text] [Related]
31. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis.
Kawano S; Matsumoto K; Hara R; Kuroda Y; Ikawa K; Morikawa N; Horino T; Hori S; Kizu J
J Infect Chemother; 2015 Jun; 21(6):476-8. PubMed ID: 25869915
[TBL] [Abstract][Full Text] [Related]
33. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.
Tanigawara Y; Kaku M; Totsuka K; Tsuge H; Saito A
J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500
[TBL] [Abstract][Full Text] [Related]
35. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
Conte JE; Golden JA; Kelley MG; Zurlinden E
Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
Kitzes-Cohen R; Farin D; Piva G; De Myttenaere-Bursztein SA
Int J Antimicrob Agents; 2002 Feb; 19(2):105-10. PubMed ID: 11850162
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
38. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.
Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F
Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851
[No Abstract] [Full Text] [Related]
39. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
[TBL] [Abstract][Full Text] [Related]
40. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.
Aitken SL; Altshuler J; Guervil DJ; Hirsch EB; Ostrosky-Zeichner LL; Ericsson CD; Tam VH
Int J Antimicrob Agents; 2015 May; 45(5):541-4. PubMed ID: 25665726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
